Left ventricular hypertrophy (LVH) is associated with an increased risk of cardiovascular complications independently of other known risk factors, but so far the predictive value of its evolution under treatment has been studied relatively little. Since 1983 we have followed up a cohort of initially untreated hypertensive patients with echocardiographic measurements of left ventricular mass (LVM). We analyzed the data on 474 patients with more than 5 years of follow-up to assess the prognostic value of LVM and its evolution during treatment for high blood pressure. A total of 40 patients were lost to follow-up. The mean follow-up period was 89 Ϯ 31 months. A cardiovascular complication was recorded in 40 individuals. There was a strong link between increased LVM and the occurrence of complications (P Ͻ .001). At least a second determination of LVM was performed in 311 patients, and the last value before the occurrence of any complication (60 Ϯ 38 months after the initial examination) was retained. In this subgroup, 28 patients presented with a cardiovascular event. There was a trend toward a reduction of the incidence of events in the group with a regression of LVH as compared to the group with persistent LVH, but there was no difference when patients were split into quartiles according to LVM evolution between baseline and followup. Thus, the reduction of LVM on treatment was not a good marker of future cardiovascular events and its seems at least premature to say that LVM fulfils all conditions for a surrogate end point in the evaluation of morbidity/ mortality in the hypertensive. Am J Hypertens 2001;14: 524 -529
L
eft ventricular hypertrophy (LVH) is associated with an increased risk of cardiovascular complications independently of other known risk factors, [1] [2] [3] [4] and there is increasing evidence that the regression of LVH after antihypertensive treatment is accompanied by an improvement in prognosis. [5] [6] [7] [8] However, it is perhaps premature to conclude that LVH represents a good surrogate end point for morbidity/mortality studies in the treatment of high blood pressure (BP). 9 It remains to be demonstrated that left ventricular mass (LVM) and cardiovascular risk are linked in a proportional manner in all populations. Since 1983, we have followed up a cohort of initially untreated hypertensive patients with good-quality echocardiographic measurements of LVM. During the first months of 1999, we analyzed the data on all patients with Ͼ 5 years of follow-up to assess the prognostic value of LVM and its progression during treatment for high BP.
Methods Population
The population was drawn from a cohort of hypertensive patients recruited since 1983 according to the following criteria: office BP Ͼ 140/90 on at least two occasions, with no history of cardiovascular complications and devoid of any associated pathology that might affect prognosis. All patients had been referred to our department before administration of any antihypertensive treatment, and all had had a good-quality echocardiographic measurement of LVM. Patients in which good echo tracings could not be obtained were not included in the cohort. Blood pressure was measured under standardized conditions (average of three measurements with a mercury sphygmomanometer after 10 min of rest in the supine position, with diastolic BP measured in phase V) by the same physician (P.G.). After these examinations, most patients were started on antihypertensive medication, which was supervised by their family physicians. These patients were reexamined in our department depending on individual needs, and LVM was measured by the same echocardiographer (P.G.). At regular intervals, the patients were contacted by telephone to determine outcome. The end point of the present study was the first 6 months of 1999, and we retained all patients who had been followed-up for at Ն 5 years. In the event of any cardiovascular complication, details were obtained from the family doctor; in the case of more than one complication in the same patient, only the first event was kept for the analysis. The following complications were recorded: angina confirmed by coronarography with at least one significant (Ͼ 70%) stenosis), myocardial infarction, heart failure prompting admission to the hospital, stroke, renal insufficiency requiring dialysis, symptomatic arteritis of the lower limbs confirmed by echo-Doppler examination, and aneurism of the abdominal aorta necessitating surgery. In the case of more than one end point, only the first one was taken into account. These data were recorded by a physician who was unaware of the initial findings (C.C.).
Echocardiographic Measurement of LVM
Left ventricular mass was measured at baseline in all patients before administration of any antihypertensive treatment. In the majority of cases, a new determination was carried out 6 to 12 months after starting the antihypertensive treatment. In the patients who had had repeated measurements of LVM during treatment, we retained the last determination under treatment before occurrence of any complication (last LVM). In all cases, LVM was measured from two-dimensional guided M-mode tracings of the left ventricle from a left parasternal view. The tracings were recorded on a high quality chart recorder running at 100 mm/sec, and at least three consecutive cycles were read according to the PENN convention. All tracings were read after coding by operators who were blind to the clinical data and the date of the examination. The LVM was calculated from the formula of Devereux and Reichek 10 and indexed to body surface area. Although this method of indexing may not be ideal, it is the most widespread ( 11, 12 ) and we employed it to allow comparison of our data with those of other reported studies. We used a cutoff of 125 g/m 2 for the definition of LVH. 
Statistical Analysis
The SPSS software package (SPSS, Chicago, IL) was employed for the statistical analysis. Groups were compared for the quantitative variables by analysis of variance with a Neumann-Keuls test when the analysis of variance was significant (P Ͻ .05) and by the 2 test for the qualitative variables. The population was split into quartiles according to baseline left ventricular mass/body surface area (LVM/BSA) and to LVM variation between baseline and the last measurement. Survival without complication of the different groups was analyzed by KaplanMeier procedures and compared using the log-rank test.
The survival without complication of the population was studied in a Cox model, which included the following parameters: age, sex, office BP and indexed LVM and their variations, weight, smoking (yes or no), hypercholesterolemia (yes or no), and diabetes (yes or no).
Results
Until 6 January 1999, our cohort included 741 hypertensive patients, out of which 474 had been followed up for Ն 5 years and who were therefore the subjects of the present study. A total of 40 patients were considered lost to follow-up, but there were no significant differences between this group and the rest of the population. The mean follow-up period was 89 Ϯ 31 months. At least one cardiovascular complication was recorded in 40 individuals: 16 with coronary artery disease (six with myocardial infarction), nine with stroke, four patients with arteritis of the lower limbs, five sudden deaths, one renal insufficiency, three patients with heart failure, and two patients with an aneurysm of the abdominal aorta necessitating surgery. There were no significant differences in treatment between the patients with or without complications. Treatments included: diet and general health measures in 2% (no complications in this group), ␤-blockers in 19%, calcium inhibitors in 14%, ACE inhibitors in 10%, diuretics in 5%, and a combination of two or more antihypertensive agents in the other cases. Prevalence of LVH was 44% in this population, 41% in the group without complications, and 75% in the group who developed a complication. Baseline variables and outcome are presented in Table 1 according to quartiles in baseline LVM/BSA. There was a strong link between LVM and the occurrence of cardiovascular complications or death. As shown in Fig. 1 , the survival-without-event curves of the groups according to baseline LVM/BSA quartiles were significantly different (P Ͻ .001). The risk of cardiovascular events is particularly increased in the fourth quartile (LVM Ͼ 143 g/m
2 ) The cutoff of 125 g/m 2 had a sensitivity of 75% and a specificity of 59% for predicting the occurrence of cardiovascular complications. In the Cox model, only age and LVM contributed independently and in a significant manner for prediction of survival without cardiovascular complications. Moreover, the pattern of left ventricular remodeling has significant consequence on the incidence of cardiovascular events. Using the partition values of 0.43 for relative wall thickness and 125 g/m 2 for LVM/BSA, the incidence of cardiovascular events was respectively of 3.7% in the group with normal left ventricle (n ϭ 215, eight events), 7.1% in the group with concentric remodeling (n ϭ 28, two events), 14.3% in the group with eccentric LVH (n ϭ 139, 20 events), and 19.2% in the group with concentric LVH (n ϭ 52, 10 events).
In this population, 311 patients had had at least a second determination of LVM, and we retained the last value before the occurrence of any complication (60 Ϯ 38 months after the initial examination and start of antihypertensive treatment). ). There was a significant but weak correlation between the reduction in LVM and the reductions in SBP (r ϭ 0.20, P Ͻ .001) and DBP (r ϭ 0.17, P ϭ .002). The mean follow-up for this population to the end point was 95 Ϯ 33 months. In this subgroup, 28 patients presented a cardiovascular complication and 12 died of cardiovascular disease. Patients who had presented with a complication had a significantly higher LVM, both on entry and during treatment, than those in the group without complications. Office SBP and age also differed significantly between the two groups. The cutoff of 125 g/m 2 on the last measurement of LVM had a sensitivity of 61% and a specificity of 58% for prediction of cardiovascular complications. In this group, only age and initial indexed LVM emerged as significant predictive variables for the Cox model including age, gender, initial values of BP and LVM and their variations at the last determinations. The event rate was lower in the group with no LVH at baseline and last LVM (n ϭ 125, 0.62 per 100 patient-years) than in the group with LVH both at baseline and last LVM (n ϭ109, 1.87 per 100 patient-years), and was intermediate in the group whose LVH had regressed at follow up (n ϭ 52, 1.1 per 100 patient-years); however, the differences between the groups failed to reach statistical significance. Baseline variables and outcome are presented in Table 2 according to quartiles in LVM evolution (baseline to last LVM) and the corresponding survival curves are presented in Fig. 2 . There was no difference in incidence of cardiovascular complications among the four groups. The same analysis was performed using the second determination of LVM 6 to 12 months after baseline instead of the last measurement, and the results were similar.
Variations in LVM between baseline and last measurement show a regression to the mean, as the first quartile (progression of LVM) correspond to the lower baseline values and the last quartile (average regression, 26 g) to the higher baseline values. (2) 5 (3) 13 (9) .02 SBP ϭ systolic blood pressure; DBP ϭ diastolic blood pressure; HR ϭ heart rate; EDD ϭ end diastolic dimension of the left ventricle; ESD ϭ end systolic dimension; ST ϭ septal thickness; PWT ϭ posterior wall thickness; LVM/BSA ϭ left ventricular mass indexed for body surface area.
Discussion
We found a link between an elevation of LVM determined by echocardiography before any antihypertensive treatment and the occurrence of cardiovascular complications in a population of hypertensive patients from the Bordeaux region. This represents the first such study conducted in France, and confirmed LVH as a strong and independent risk factor for cardiovascular complications. On the other hand, the relation between progression of the LVM and the prognosis was less apparent. In our series, there was a tendency for a higher incidence of complications in the patients whose LVH persisted despite treatment as compared to those whose LVH regressed; however, the patients whose LVM was reduced by treatment did not develop significantly fewer complications than did those with stable or increased LVM. The predictive value of the progression of LVM under treatment has been little studied and, to our knowledge, only three echocardiographic studies have been published in full. In the study of Yurenev et al, 5 304 hypertensive patients with LVH were followed-up for 4 years and 54 of them developed cardiovascular complications. These patients were divided into three groups as a function of the extent of the LVM at the end of this 4-year period: one with regression of LVH (Ͼ 20 g reduction in LVM), the second with no change in LVM, and the third with progression of LVM (Ͼ 20 g increase). The latter group presented significantly more complications than did the other two groups. In the study by Muiesan et al, 7 151 hypertensive patients were followed-up over a mean period of 10 years with an echocardiographic study on entry and at the end of the follow-up period. In this group, 23 patients developed a cardiovascular complication. The 34 patients with a persistent LVH presented with significantly more complications than did the 32 patients whose LVH regressed (13 v 4, P ϭ .01). However, a limitation of this study was that the last echocardiographic determination of LVM was made after the possible occurrence of a complication. Because the study by Verdecchia et al 8 most resembled ours, we employed the same criteria for LVH. In this study, 430 hypertensive patients were followed-up for an average of 3.2 years, and 31 cardiovascular com- plications were recorded with no deaths. The second echocardiographic measurement of LVM was made on average 2.8 years after the initial examination. Verdecchia et al reported that the 285 patients with a reduction in LVM under treatment presented with significantly fewer complications (n ϭ 15) than did the 145 patients whose LVM remained stable or increased (n ϭ 16; P ϭ .03). The populations in these four studies were quite similar, with comparable ages and blood pressures. The prevalence of LVH appeared to be higher in our population than in that of Verdecchia et al (44% v 26%) using the same criteria, but was identical to that of Muiesan et al with different criteria. There was also a comparable response of BP and LVM to treatment in the four studies. The main differences were in the interval between the last echocardiographic measurement of LVM and the duration of follow-up. In the studies of Yurenev et al and Muiesan et al, the last measurements of LVM were made at the end point of the follow-up period and, in the study of Muiesan et al, the last determination may have been made after occurrence of a complication. In the study of Verdecchia et al, the last measurement of LVM preceded any complication, but the interval between this last measurement and the end of the follow-up period was relatively short (5 to 6 months). In our study, the second determination of LVM preceded the end point or the occurrence of a complication by an average of 30 months; thus, we lack information on LVM in this interval, which may account for the absence of predictive value of a reduction in LVM under treatment for cardiovascular risk. Another phenomenon may contribute to reduce the predictive value of a variation in LVM. As observed in our study, the variability in LVM measurements may cause a regression to the mean in serial measurements and thus a decrease in LVM in patients with high baseline value but an increase in LVM in patients with low baseline values independently of the effect of treatment and of risk reduction. Finally, it should be borne in mind that in all four studies there were relatively few observed events, and we could not conclude on the basis of our results that LVM fulfills all conditions for a surrogate end point in the evaluation of morbidity/mortality in the hypertensive patient. There does not appear to be a strict relation between progression of LVM and cardiovascular risk in patients treated for high blood pressure. Our results are more in favor of an increase in cardiovascular risk above a certain cutoff for LVM. The patients with LVM Ͼ 125 g/m 2 had a greater tendency to develop complications than did the patients whose LVM was maintained below this value, and patients presenting with complications under antihypertensive treatment had a higher LVM than did those without complications. However, because of the low number of complications observed, we could not establish a truly predictive cutoff value for LVM; this will have to await the results of further controlled and prospective studies on larger populations. 
